68Ga-PSMA PET in prostate cancer: a systematic review and meta-analysis of the observer agreement
- PMID: 34767046
- DOI: 10.1007/s00259-021-05616-5
68Ga-PSMA PET in prostate cancer: a systematic review and meta-analysis of the observer agreement
Abstract
Purpose: The performance of 68 Ga-PSMA PET/CT-MR has been evaluated in prostate cancer (PCa), showing significant results. However, even a technically accurate imaging procedure requires a high interobserver agreement in its interpretation to implement in patients' management. This study aims to perform a systematic review and meta-analysis on the interobserver variability in 68 Ga-PSMA PET/CT-MR imaging in PCa patients.
Methods: We conducted a systematic review and meta-analysis on the interobserver variability, including studies: (1) providing Kappa (K) as the inter-observer agreement test or the essential data to calculate it, (2) providing the K confidence interval or the essential crude data to calculate it, (3) measuring K statistic based on the appropriate use criteria for the inter-observer agreement.
Results: Twelve studies, providing 1585 68 Ga-PSMA PET/CT-MR studies reviewed by 62 independent readers, were included. In general, the pooled inter-observer agreement was interpreted as substantial for all analyzed groups, including tumoral lesions in the prostate bed, lymphadenopathies, bone metastasis, and soft-tissue metastasis (all between 0.6 and 0.8). The regional lymphadenopathy group (0.74) obtained the highest agreement, while the lowest was for soft tissue metastasis (0.65).
Conclusion: This study showed a substantial interobserver agreement in the overall interpretation and detecting locoregional and distant involvement with 68 Ga-PSMA PET/CT-MR in PCa patients.
Keywords: Agreement; Meta-analysis; PET; PSMA; Variability.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
References
-
- Rawla P. Epidemiology of prostate cancer. World J Oncol. 2019;10:63. - DOI
-
- Van den Broeck T, van den Bergh RC, Briers E, Cornford P, Cumberbatch M, Tilki D, et al. Biochemical recurrence in prostate cancer: the European association of urology prostate cancer guidelines panel recommendations. Eur Urol Focus. 2020;6:231–4. - DOI
-
- Mohler JL, Antonarakis ES, Armstrong AJ, D’Amico AV, Davis BJ, Dorff T, et al. Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology. J NCCN. 2019;17:479–505.
-
- Trabulsi EJ, Rumble RB, Jadvar H, Hope T, Pomper M, Turkbey B, et al. Optimum imaging strategies for advanced prostate cancer: ASCO guideline. J Clin Oncol. 2020;38:1963. - DOI
-
- Annunziata S, Pizzuto DA, Treglia G. Diagnostic performance of PET imaging using different radiopharmaceuticals in prostate cancer according to published meta-analyses. Cancers. 2020;12:2153. - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
